Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 2-Part, Phase 1/2, Randomized, Observer-Blinded Study To Evaluate The Safety And Immunogenicity Of A SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Or Without MATRIX-M Adjuvant In Healthy Subjects

Next Previous
Search
Trial Profile

A 2-Part, Phase 1/2, Randomized, Observer-Blinded Study To Evaluate The Safety And Immunogenicity Of A SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Or Without MATRIX-M Adjuvant In Healthy Subjects

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 08 Jun 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs COVID-19 vaccine adjuvanted Novavax (Primary) ; Matrix M
  • Indications COVID 2019 infections
  • Focus Adverse reactions; First in man; Pharmacodynamics; Registrational
  • Sponsors Novavax

    • Most Recent Events

    • 02 Jun 2023 Results(n=1283) assessing Immunogenicity and safety of a fourth homologous dose of NVX-CoV2373 published in the Vaccine
    • 12 May 2023 Results published in the Journal of Infectious Diseases
    • 01 Nov 2022 Results(n= 1282) of a secondary analysis assessing the immunogenicity and safety of a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine published in The Lancet Infectious Diseases

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top